Instead of picking individual seed deals, USVC invests in top seed-stage fund managers. It then positions itself as the go-to capital partner for those managers' larger, later-stage follow-on rounds, creating a scalable and proprietary deal pipeline.

The fundamental risk profile shifts dramatically between venture stages. Early-stage investors bet against business failure, an idiosyncratic risk unique to each company. Late-stage investors are primarily betting on public market multiples and macro sentiment holding up—a systematic risk affecting all late-stage assets simultaneously.

Unlike seed-only funds, multi-stage investment firms have a structural advantage: they can rectify a mistaken pass on an early round by investing later. This provides a crucial second chance to partner with founders they initially misjudged, as Andreessen Horowitz did after passing on Solana's first round.

Instead of passively waiting for pitches, proactive VCs like Foresight Capital build new companies by acquiring promising assets. They actively source clinical or later-stage assets, particularly from Asia where market dynamics are favorable, and then build a new company around them with a proven entrepreneur from their network.

A large, multi-stage VC firm's growth fund serves as a risk mitigation tool. The ability to concentrate capital into late-stage winners covers losses from a higher volume of early-stage mistakes, allowing the firm to be more "promiscuous" and take more shots at Series A.

OMX Ventures invests across tools, diagnostics, and therapeutics because "tools lead to new insights that lead to new products." This strategy provides a "front row seat" to emerging technologies, allowing them to understand a new tool's power and application before the broader market. This information arbitrage leads to smarter investments across their entire portfolio.

The biotech venture model is built on syndication, not competition. As a drug progresses, capital requirements balloon to hundreds of millions for late-stage trials, far exceeding any single VC's capacity. This structural reality forces firms to co-invest and partner throughout a company's lifecycle.

Thrive's late-stage philosophy starts with qualitative conviction in the team and product. Quantitative analysis is used to confirm this hypothesis, not generate it. This approach builds resilience against short-term metric fluctuations that cause purely quantitative investors to lose confidence, allowing for bolder, long-term bets.

The venture capital landscape is bifurcating. Large, multi-stage funds leverage scale and network, while small, boutique funds win with deep domain expertise. Mid-sized generalist funds lack a clear competitive edge and risk getting squeezed out by these two dominant models.